Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Short Sleep Study

6 de agosto de 2026 actualizado por: Danisco

The Short Sleep Study: A Non-interventional Study of Fecal Microbiota in Natural Short Sleepers

Natural Short Sleepers are defined as individuals who sleep fewer than 6 hours per night without any impact on health or daytime mental fatigue levels. Emerging evidence suggests that, in the general population, the gut microbiota would be negatively influenced by this sleep duration. It is possible that Natural Short Sleepers have a distinct gut microbiome. Identifying differences in microbiota composition may lead to an opportunity to improve health outcomes in those with inadequate or poor sleep.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Tipo de estudio

De observación

Inscripción (Estimado)

34

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Florida
      • Miami, Florida, Estados Unidos, 33155
        • Reclutamiento
        • Global Life Research Network
        • Contacto:
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02111
        • Reclutamiento
        • Lindus Health
        • Contacto:
    • New York
      • Garden City, New York, Estados Unidos, 11530
        • Reclutamiento
        • AccuMed
        • Contacto:
          • Leanne Cossu
          • Número de teléfono: 516-746-2190
          • Correo electrónico: accumed@aol.com
    • Texas
      • Houston, Texas, Estados Unidos, 77082
        • Reclutamiento
        • New Dawn Wellness and Medical Research Center
        • Contacto:
          • Moses Ukazu
          • Número de teléfono: 281-809-5467
          • Correo electrónico: mukazu@ndwmc.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Natural Short Sleepers are defined as individuals who sleep between 4 and 5.5 hours per night without any impact on health or daytime mental fatigue levels.

Descripción

Inclusion:

  1. Men between 20 - 50 years of age and pre-menopausal women between 20 - 45 years of age (inclusive).
  2. Consistent schedule during daytime hours.
  3. Body Mass Index (BMI) 18.5 - 35 kg/m2 (inclusive).
  4. Good physical and mental health as established by self-reported medical history and evaluated by a study investigator.
  5. Willingness to maintain and record their general habits, eating, and daily activity/exercise pattern for the study period.
  6. Willingness to maintain typical sleep hygiene patterns (e.g. sleep location, temperature, environment).
  7. Willingness to maintain their current pattern of alcohol consumption for the duration of the study.
  8. Willing and able to participate fully in all aspects of the study and complete all study procedures, including providing signed informed consent.
  9. Willing and able to attend two in-person visits at a trial site
  10. Completes all required procedures (screening questionnaire and ePROs) during the 14-day screening period 10a. Two instances of the sleep diary and Karolinska Sleepiness Scale may be missed by the participant without impacting eligibility
  11. Has regular bowel habits, on at least 5 days a week.
  12. Pittsburgh Sleep Quality Index (PSQI) global score of ≤7 and a sleep efficiency score of ≥80%, self-reported during the screening period. Additionally, no more than one score of 3 is permitted across Question 5 sub-items, and no score of 3 is permitted in Question 10 sub-items, if a bed partner is present
  13. Sleep, on average, 4-5.5 hours per night, verified via participant self-report during the screening period. If the participant's average is within the 4-5.5 hour range but slept more than 5.5 hours on any of the nights their eligibility will be assessed per PI/Sponsor discretion. Note: Oura ring data from the run-in period will be reviewed to confirm eligibility based on PI/Sponsor discretion.
  14. Report feeling refreshed with no desire to nap during the daytime, with a score of ≤4 on the Epworth Sleepiness Scale (ESS) evaluated during the screening period.
  15. Average KSS Score of 1-3 during the screening period.

Exclusion:

  1. Ever diagnosed with or self-reports a sleep disorder, including sleep apnea, habitual snoring (defined as loud, persistent snoring 3 or more nights per week), insomnia, narcolepsy, or parasomnias.
  2. Extreme chronotypes, those who regularly go to sleep prior to 8:00pm.
  3. Any current diagnosed or self-reported gastrointestinal disorder, including Crohn's disease, ulcerative colitis, celiac disease, IBS, or functional bowel disorder or chronic heartburn.
  4. Regularly wakes up during the night 5 or more times per night for a cumulative amount of 30 minutes as observed via self-report during the screening period, per PI discretion.
  5. Currently taking medications (including over-the-counter medications) or dietary supplements that, in the investigator's opinion, may affect the participants' microbiome or sleep.
  6. Have taken in the last 3 months medications (including over-the-counter medications) or dietary supplements that, in the investigator's opinion, may affect the participants' microbiome or sleep.
  7. Neurodegenerative diseases (including multiple sclerosis, Parkinson's disease, Alzheimer's disease, dementia).
  8. Recent history (past year) of alcohol abuse or dependence. Defined as regularly drinking more than 12 drinks for females and more than 20 drinks for males per week and based on PI discretion.
  9. Drug abuse or dependence, including consistent recreational substance use such as marijuana.
  10. Binge drinking behavior, defined as 4 or more alcoholic drinks for women or 5 or more alcoholic drinks for men in one sitting on 2 or more occasions, within the past 1 month with final decision per PI discretion.
  11. Recent history (current use or within the past 1 month) of smoking, vaping or other use of nicotine-containing products.
  12. Diagnosed neuropsychiatric disorders or symptoms possibly affecting sleep e.g. (generalized anxiety disorder (GAD), major depressive disorder (MDD), bipolar disorder, schizophrenia)
  13. Any use of systemic antibiotics in the past 3 months. This does not include topical or targeted antibiotic use (ointment, spray, eye drop, ear drop).
  14. Any use of probiotic supplements in the past 2 weeks.
  15. Any use of proton pump inhibitors (PPIs) in the past 2 weeks.
  16. Any use of laxatives or antidiarrheals in the past 4 weeks.
  17. Any use of non-steroidal anti-inflammatory drugs (NSAIDs) for 5 or more consecutive days in the past 4 weeks.
  18. Pregnant or breastfeeding or planning to become pregnant.
  19. Personal circumstances affecting stress or sleep (e.g. serving as a caretaker/required to wake up during sleep/major change in personal life). Note: Life situations causing stress or challenges in sleep that are considered shortterm, per PI discretion, may be considered for re-screening 4 weeks after the life situation has resolved, meaning it is no longer causing stress or challenges in sleep.
  20. Planned overnight travel during the study.
  21. Females experiencing perimenopausal or menopausal symptoms, or those who have been diagnosed as perimenopausal or menopausal by a physician.
  22. Any diagnosed condition or undiagnosed symptom which disrupts sleep, including, but not limited to, hyperthyroidism, night sweats, restless legs, or poorly controlled allergic rhinitis.
  23. Varying work schedule and/or shift workers who work overnight shifts (e.g. 3rd shift, working late night to early morning hours).
  24. Any other personal or medical condition that the investigator believes may bias or confound the results.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Natural Short Sleepers
Natural short sleepers (NSS) sleep on average <6 hours per night, but feel no need to sleep longer, and do not show signs of daytime sleepiness or fall asleep in low stimulus environments.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Microbiome characterization of the short sleeper population
Periodo de tiempo: baseline through day 10 of the study period.
Identify a specific fecal microbiota composition related to short sleep
baseline through day 10 of the study period.
Comparison of natural short sleeper microbiomes to participants from the night owl study.
Periodo de tiempo: From baseline through day 10 of the study period.
Compare microbiome (composition and function) of natural short sleeprs to those individuals enrolled into the night owl study.
From baseline through day 10 of the study period.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

23 de octubre de 2025

Finalización primaria (Estimado)

1 de diciembre de 2026

Finalización del estudio (Estimado)

1 de abril de 2027

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

30 de abril de 2026

Publicado por primera vez (Actual)

5 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

7 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de agosto de 2026

Última verificación

1 de noviembre de 2025

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • IFF-NO-002

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir